Fulgent Genetics Has Another Blast Out Quarter

  • Fulgent produced another stellar quarter and while its Covid business will shrink, it isn’t going away anytime soon as it shifts to asymptotic and surveillance testing.
  • Meanwhile, the company is leveraging its success in Covid in its NGS business in multiple ways.
  • The company is amassing a great cash fortune, and Ming Hsieh is just the right person to put that to productive use.
  • Learn More »